Oral News and Research

RSS

Fiber-reinforced composite material holds promise for oral applications and orthopedics

New materials and new technologies offer opportunities to bring implant dentistry to more patients. Fiber-reinforced composite is a new material that promises advantages for use in oral and craniofacial applications as well as in orthopedics. Discovering how it responds to stress and strain can help gauge its usefulness.

22 Apr 2011

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed U.S. neurologists selected Biogen Idec/Elan's Tysabri as the most effective therapy for the treatment of relapsing-remitting multiple sclerosis, when compared to other currently available agents.

22 Apr 2011

Early surgery, timely treatment and prenatal diagnosis can help prevent oral clefts

Affecting more than 7,000 U.S. babies each year, cleft lip and/or cleft palate are the second most common birth defect, the cause of which continues to mystify scientists despite growing evidence of a complex interplay of genetic, environmental and lifestyle factors.

22 Apr 2011

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced commencement of a proof-of-concept clinical trial of its lead candidate ganaxolone for the treatment of posttraumatic stress disorder.

22 Apr 2011

USPTO issues patent to Oragenics ProBiora3 for oral care

Florida-based biopharmaceutical company Oragenics, Inc. announced today the issuance of patent number 7931892 from the United States Patent and Trademark office for ProBiora3, a proprietary blend of naturally occurring oral bacteria shown to produce a wide range of oral care benefits.

22 Apr 2011

Contraception drospirenone raises risk for blood clots

Two new drug safety studies conducted by researchers at Boston University School of Medicine (BUSM) provide strong evidence that women taking oral contraception with drospirenone have an increased risk of nonfatal venous thromboembolism, or blood clots, compared to women taking oral contraception with levonorgestrel.

21 Apr 2011

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Merck and Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today the initiation of a Phase III clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine.

21 Apr 2011

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2011 results.

21 Apr 2011

Opinions: Eliminating TB; HIV prevention trial; Reducing stillbirths; Foreign aid, global stability; Safe injection sites

In a U.S. News & World Report opinion piece, African Health Ministers Aaron Motsoaledi of South Africa, Mphu Ramatlapeng of Lesotho, and Benedict Xaba of Swaziland call upon the international community to join with them in the fight to rid the world of tuberculosis (TB). "That goal might seem overambitious or unrealistic. [But i]t's not," they write

21 Apr 2011

Neurelis completes dosing in intranasal diazepam formulation study

Neurelis, Inc. today announced the completion of subject dosing in a randomized crossover study assessing diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection.

21 Apr 2011

Anavex: First-in-human dosing cmmenced in ANAVEX 2-73 clinical trial for Alzheimer’s

Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease. “We are pleased that the first volunteers have been dosed with the study drug, according to the study protocol, and no adverse events have been recorded post dosing to date," said Dr. Ozkan Yalkinoglou, Medical Director of ABX-CRO.

20 Apr 2011

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.

20 Apr 2011

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study (DISCOVER-1) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). The pivotal study is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

20 Apr 2011

Researchers to wind down HIV prevention trial in women after interim results find drug not offering protection from HIV

Researchers on Monday announced they were calling off a trial to test whether taking an oral HIV drug reduces the risk of HIV infection in women after interim analysis of the study showed women taking the medication were no less likely to become infected with HIV than those who were not taking the medicine, the Associated Press reports.

20 Apr 2011

Rituxan receives FDA approval for treating two rare diseases

The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).

20 Apr 2011

Dental diagnosis and treatment for snoring and sleep apnoea

Over seven million people in Spain are at risk of developing sleep apnoea (SA), a health problem caused by obstructed air intake during sleep.

20 Apr 2011

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first human phase 2 study of masitinib carried-out in the treatment of Alzheimer's disease.

20 Apr 2011

Chembio initiates FDA Modular PMA process for DPP HIV 1/2 Screening Assay

Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported it recently filed the first module of its Pre-Marketing Approval (PMA) application to the United States Food & Drug Administration for its DPP® HIV 1/2 Screening Assay.

19 Apr 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson today announced sales of $16.2 billion for the first quarter of 2011, an increase of 3.5% as compared to the first quarter of 2010.

19 Apr 2011

Drospirenone doesn't carry any risk of gall bladder disease

Drospirenone, the top-selling oral contraceptive marketed as Yaz or Yasmin in the U.S. and Canada, doesn't carry any more risk of gall bladder disease than the older generation of birth control pills, despite claims by some consumers and lawyers in both countries, according to a new study by University of British Columbia and Vancouver Coastal Health Research Institute researcher Mahyar Etminan.

19 Apr 2011

Oral News and Research

Fiber-reinforced composite material holds promise for oral applications and orthopedics

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Early surgery, timely treatment and prenatal diagnosis can help prevent oral clefts

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

USPTO issues patent to Oragenics ProBiora3 for oral care

Contraception drospirenone raises risk for blood clots

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Opinions: Eliminating TB; HIV prevention trial; Reducing stillbirths; Foreign aid, global stability; Safe injection sites

Neurelis completes dosing in intranasal diazepam formulation study

Anavex: First-in-human dosing cmmenced in ANAVEX 2-73 clinical trial for Alzheimer’s

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Researchers to wind down HIV prevention trial in women after interim results find drug not offering protection from HIV

Rituxan receives FDA approval for treating two rare diseases

Dental diagnosis and treatment for snoring and sleep apnoea

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

Chembio initiates FDA Modular PMA process for DPP HIV 1/2 Screening Assay

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Drospirenone doesn't carry any risk of gall bladder disease

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News